Copyright
©2010 Baishideng.
World J Hepatol. Feb 27, 2010; 2(2): 58-64
Published online Feb 27, 2010. doi: 10.4254/wjh.v2.i2.58
Published online Feb 27, 2010. doi: 10.4254/wjh.v2.i2.58
Table 2 Recent phase II studies of chemotherapy for biliary tract carcinoma
| Agents | n | RR (%) | PFS (M) | MST (M) | Authors | Year |
| Gemcitabine | ||||||
| 1000mg/m2, 30-min infusion | 25 | 36 | 6.9 | Gallardo | 2001 | |
| 24 | 12.5 | 2.5 | 7.2 | Lin | 2003 | |
| 40 | 17.5 | 2.6 | 7.6 | Okusaka | 2006 | |
| Fluoropyrimidine | ||||||
| Capecitabine | 26 | 19 | 8.1 | Patt | 2004 | |
| S-1 | 19 | 21 | 3.7 | 8.3 | Ueno | 2004 |
| S-1 | 40 | 32.5 | 3.7 | 9.4 | Furuse | 2008 |
| Others | ||||||
| Docetaxel | 24 | 20 | 6.0 | 8.0 | Papakostas | 2001 |
| CPT-11 | 36 | 8 | 2.7 | 6.1 | Alberts | 2002 |
| Erlotinib | 42 | 8 | 2.6 | 7.5 | Philip | 2006 |
| Gemcitabine + fluoropyrimidine | ||||||
| Gem/5FU | 27 | 33 | 3.7 | 5.3 | Knox | 2004 |
| Gem/5FU/LV | 30 | 20 | 3.7 | 4.7 | Hsu | 2004 |
| Gem/5FU/LV | 42 | 12 | 4.6 | 9.7 | Alberts | 2005 |
| Gem/capecitabine | 45 | 31 | 7.0 | 14.0 | Knox | 2005 |
| Gem/capecitabine | 45 | 32 | 6.0 | 14.0 | Cho | 2005 |
| Gemcitabine + platinum | ||||||
| Gem/cisplatin | 30 | 37 | 4.1 | 4.6 | Doval | 2004 |
| Gem/cisplatin | 40 | 28 | 4.7 | 8.4 | Thongprasert | 2005 |
| Gem/cisplatin | 29 | 35 | 3.0 | 11.0 | Kim | 2006 |
| Gem/cisplatin | 27 | 33 | 5.6 | 10.0 | Park | 2006 |
| Gem/oxaliplatin | 33 | 33 | 5.7 | 15.4 | Andre | 2004 |
| Gem/oxaliplatin/bevacizumab | 26 | 29 | 7.6 | Clark | 2007 | |
| Fluoropyrimidine + platinum | ||||||
| Capecitabine/oxaliplatin | 65 | 20 | 6.5 | 12.8 | Nehls | 2006 |
| S-1/cisplatin | 51 | 30 | 4.8 | 8.7 | Kim | 2007 |
- Citation: Morise Z, Sugioka A, Tokoro T, Tanahashi Y, Okabe Y, Kagawa T, Takeura C. Surgery and chemotherapy for intrahepatic cholangiocarcinoma. World J Hepatol 2010; 2(2): 58-64
- URL: https://www.wjgnet.com/1948-5182/full/v2/i2/58.htm
- DOI: https://dx.doi.org/10.4254/wjh.v2.i2.58